Accelerating The Path To Precision Medicine in Drug Discovery through AI

سال انتشار: 1404
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 49

فایل این مقاله در 8 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

HESPCONF08_052

تاریخ نمایه سازی: 8 دی 1404

چکیده مقاله:

Generative artificial intelligence (AI) entered mainstream discourse with the release of ChatGPT, yet AI and machine learning (ML) have long been embedded in pharmaceutical research and development (R&D). These technologies now span nearly every phase of biopharmaceutical R&D, including target identification, compound optimization, clinical trial design, regulatory documentation, supply chain logistics, and post-marketing surveillance. Although precision medicine is still often described as a “futuristic” paradigm in peer-reviewed literature, the integration of AI is rapidly steering drug discovery toward individualized, patient-centric models. Generative AI, while dominant in consumer platforms, represents only one subset of a broader computational ecosystem. The pharmaceutical industry has relied on predictive modeling for years, and recent advances in ML have enabled researchers to stratify patient populations, forecast mechanisms of action, predict differential drug responses, including toxicity, and refine dosing strategies. These innovations are accelerating the shift from generalized therapeutics to precision medicine tailored to molecular, genetic, and phenotypic profiles. Moreover, the convergence of AI with multi-omics data, real-world evidence, and digital biomarkers is enhancing the resolution of patient stratification and therapeutic targeting. As AI systems become more interpretable and data integration improves, their role in clinical decision-making and translational research is expected to expand, bridging the gap between bench and bedside. Ultimately, AI-driven precision medicine holds the potential to reduce drug development timelines, lower costs, and improve long-term patient outcomes through more effective and safer therapies. This article explores accelerating the precision medicine path in drug discovery through artificial intelligence.

نویسندگان

Amirreza Talebi

Medical Doctor, Resident of Radiology, Tehran University of Medical Sciences, Tehran, Iran

Pouyan Asadi

Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Ali Shekarian

Department of Computer and Data Sciences, Faculty of Mathematical Sciences, Shahid Beheshti University, Tehran, Iran

Sobhan Salari

Master student in Geopolitics at Dafoos University, Tehran, Iran

Rabee Movagharnia

Department of Genetics and Biotechnology, School of Biological Sciences, Varamin-Pishva Branch, Islamic Azad University, Varamin, Iran